Abstract
Pharmacoepidemiology and Drug SafetyEarly View LETTER TO THE EDITOR Kill your darlings: Stop using the terms retrospective and prospective Mikkel Zöllner Ankarfeldt, Corresponding Author Mikkel Zöllner Ankarfeldt mikkelza@gmail.com Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark Correspondence Mikkel Zöllner Ankarfeldt, Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Hovedvejen opgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Copenhagen, Denmark. Email: mikkelza@gmail.comSearch for more papers by this authorBenedikte Irene von Osmanski, Benedikte Irene von Osmanski Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark DLI Market Intelligence, Copenhagen Ø, DenmarkSearch for more papers by this authorKim Blond, Kim Blond Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, DenmarkSearch for more papers by this author Mikkel Zöllner Ankarfeldt, Corresponding Author Mikkel Zöllner Ankarfeldt mikkelza@gmail.com Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark Correspondence Mikkel Zöllner Ankarfeldt, Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Hovedvejen opgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Copenhagen, Denmark. Email: mikkelza@gmail.comSearch for more papers by this authorBenedikte Irene von Osmanski, Benedikte Irene von Osmanski Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark DLI Market Intelligence, Copenhagen Ø, DenmarkSearch for more papers by this authorKim Blond, Kim Blond Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, DenmarkSearch for more papers by this author First published: 03 February 2023 https://doi.org/10.1002/pds.5598Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Early ViewOnline Version of Record before inclusion in an issue RelatedInformation
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
